Proteins and Peptides

25 Oct 2018 Scarless Laboratories Receives FDA Clearance to Initiate Phase I/IIa Trial of SLI-F06 Peptide for Scar Reduction
24 Oct 2018 Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease
23 Oct 2018 Medicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European Society for Medical Oncology 2018 Congress
22 Oct 2018 amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress
21 Oct 2018 Viela Bio Announces Late-Breaking Abstract Acceptance for VIB4920, a Novel Engineered CD40L Antagonist, at the 2018 ACR/ARHP Annual Meeting
19 Oct 2018 Kuros Biosciences advances its Fibrin-PTH (KUR-113) spinal fusion product candidate program
19 Oct 2018 Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
19 Oct 2018 Novaliq Announces Positive Topline Results for Its CyclASol® Phase 2B/3 Essence Trial in Patients with Dry Eye Disease
19 Oct 2018 Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
16 Oct 2018 Peptilogics Receives Regulatory Approval to Initiate First-in-Human Safety Study for Therapeutic Peptide PLG0206
10 Oct 2018 Fresenius Kabi’s pegfilgrastim biosimilar candidate MSB11455 met its primary endpoints in the two pivotal clinical studies
06 Oct 2018 FDA Approves Revcovi™, a New Enzyme Replacement Therapy Developed by Leadiant Biosciences, for the Treatment of ADA-SCID in Pediatric and Adult Patients
04 Oct 2018 Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
02 Oct 2018 Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes
02 Oct 2018 Inotrem Announces Positive Results From the Phase IIa Study of Its Lead Compound, Nangibotide (LR12), in the Treatment of Septic Shock
02 Oct 2018 Torque Announces the Presentation of Preclinical Data for Deep IL-15 Primed T Cells Demonstrating Superior T Cell Expansion, Persistence, and Safety Compared with Systemically Administered IL-15
02 Oct 2018 FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
30 Sep 2018 New phase 2 data for somapacitan demonstrate its potential as an efficacious once-weekly treatment for childhood growth hormone deficiency
27 Sep 2018 Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout
27 Sep 2018 Hansa Medical Reports Positive Final Top Line Results from Two Phase 2 Studies of Imlifidase for Kidney Transplantation
27 Sep 2018 Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children
26 Sep 2018 Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis
26 Sep 2018 Coherus BioSciences Receives European Commission Approval for UDENYCA™ (Pegfilgrastim Biosimilar)
26 Sep 2018 Bydureon receives positive EU CHMP opinion for EXSCEL cardiovascular outcomes data
24 Sep 2018 AzurRx BioPharma Announces Positive Outcome with MS1819-SD Showing Statistically Significant Efficacy in a Phase IIa Exocrine Pancreatic Insufficiency Trial in Chronic Pancreatitis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up